TJ Chao, MPAS, PA-C

Not every flare signals treatment failure. The panel distinguishes manageable fluctuations from true loss of response and weighs how comorbidities and insurance shape next-line biologic selection.

A second patient, initially helped by adalimumab, shows how HS can outpace a first-line biologic over time. The panel discusses recognizing secondary failure and rebuilding a treatment plan.

Setting realistic timelines and reading quality of life matter as much as counting lesions. The panel also flags a common pitfall: mistaking healing pigment changes for active disease.

Black box warnings, screening requirements, and real-world experience all shape which biologic fits a given patient. The panel applies these safety considerations directly to the first case.

Adalimumab, secukinumab, and bimekizumab each carry distinct trial populations and response rates. The panel reviews years of efficacy and safety data behind today's approved HS biologics.

A 29-year-old with years of axillary and groin disease illustrates how psychosocial toll, not just visible lesions, should guide the decision to escalate beyond conventional HS therapy.

Three FDA-approved biologics now intercept the inflammatory cascade at different points, yet Dr. Laura Bush argues a calm exam can understate real disease burden. The panel discusses when history should outweigh appearance.

Hidradenitis suppurativa often goes undiagnosed for years while patients quietly absorb pain, odor, and isolation. The panel examines why recognizing these signals early changes everything that follows.

TJ Chao, MPAS, PA-C, discusses tips for educating patients and raising awareness about prurigo nodularis, focusing on the importance of informing patients about the role of systemic treatments and empowering them to make informed decisions about their care.

TJ Chao, MPAS, PA-C, discusses how to approach conversations with patients about starting systemic therapy for prurigo nodularis, emphasizing the importance of setting realistic treatment expectations, promoting long-term adherence, and providing tips for managing biologic agents administered on a bimonthly or monthly basis.

TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.

TJ Chao, MPAS, PA-C, discusses how treatment goals for prurigo nodularis should be based on disease severity and comorbidities, with adjustments to the treatment approach to optimize patient outcomes.

A collection of clinical insights on prurigo nodularis, exploring awareness and educational efforts as well as trends in treatment.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Clinicians analyze long-term efficacy data in psoriasis treatments, focusing on how they communicate and contextualize information about treatment duration to their patients.

Physicians examine the enduring effectiveness and key findings from the POETYK PSO-1 clinical trials, evaluating their impact on the evolving landscape of psoriasis treatment options.

Medical experts explore approaches for addressing suboptimal outcomes in systemic psoriasis treatments, including methods to enhance therapeutic efficacy and criteria for transitioning to alternative treatments.

Dermatology experts examine the role of IL-17 inhibitors in psoriasis management, focusing on treatment strategies, swift clinical responses, and their effectiveness across various anatomical sites affected by plaque psoriasis.

Medical professionals discuss ongoing clinical trials and novel medications for the treatment of psoriasis.

Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.

This professional summary discusses the definitions of loss of response and loss of efficacy in patient therapy, while also comparing response rates across different psoriasis treatments.

Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Key opinion leaders explore the management of plaque psoriasis, addressing treatment-related challenges and emphasizing the importance of effective communication for informed decision-making in therapy selection.

The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.

Medical experts specializing in plaque psoriasis offer a comprehensive overview of the current treatment landscape, its evolution, and the disease's psychological and physical impacts.

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies. Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. Additionally, the discussion explores strategies for communicating treatment mechanisms to patients and fostering collaborative engagement in the treatment selection process.